Kenvue Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kirk L. Perry
- Full Time Employees
- 22,000
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 1 Kenvue Way Summit NJ United States of America 07901
- IPO Date
- May 4, 2023
- CIK
- 0001944048
- Website
- kenvue.com
- Similar Companies
- Business
- Kenvue Inc. Kenvue Inc. (KVUE) operates as the world's largest pure-play consumer health company by revenue, focusing on science-backed everyday care products that serve over 1.2 billion people daily across more than 100 countries including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company manages three core segments: Self Care, offering cough, cold and allergy remedies, pain care, digestive health, smoking cessation, eye care, and related products under brands such as Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSL, Rhinocort, Calpol, and Zyrtec; Skin Health and Beauty, providing face and body care, hair, sun, and other solutions via Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX; and Essential Health, encompassing oral care, baby care, women’s health, wound care, and other items through Listerine, Johnson’s, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash. Incorporated in 2022 as a spin-off from Johnson & Johnson Johnson & Johnson and headquartered in Summit, New Jersey, Kenvue draws on a heritage exceeding 135 years in consumer health innovation. In November 2025, Kimberly-Clark Corporation Kimberly-Clark Corporation agreed to acquire Kenvue in a $48.7 billion cash-and-stock transaction valued at approximately $21.01 per share, representing a 33% premium to recent trading levels and creating a combined consumer health and wellness entity with projected $2.1 billion in annual synergies by 2028, subject to regulatory approvals expected in the second half of 2026. Earlier in 2025, Kenvue opened its new 290,000-square-foot global headquarters in Summit, New Jersey, featuring a 100,000-square-foot Science and Innovation Lab to consolidate operations, accelerate R&D, and enhance proximity to talent and consumers; launched the Tylenol Proactive Support supplement line for joint care; initiated the Total Quit campaign advocating tobacco and nicotine regulation; and appointed Kirk Perry as permanent CEO following a strategic review amid leadership transitions.
Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.58
US FDA approves over-the-counter Tylenol combination pill for pain relief
Kenvue to Announce Second Quarter 2026 Results on August 6, 2026
An Overlooked Dividend King With a 54-Year Winning Streak Worth Buying Now
US appeals court revives private lawsuits linking Tylenol to autism, ADHD
This 4.5%-Yielding Dividend Stock Is Beating the S&P 500 and the Nasdaq. 3 Reasons That Can Continue in the Second Half of 2026
2 Dividend Kings to Buy and Hold Forever
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
5 Beauty & Cosmetics Stocks to Buy for a Stable Portfolio in 2H 2026
5 High-Yielding Dividend Kings Retirees and Boomers Can Buy Today and Safely Hold Forever
Where to Put $1,000 When the Market Is This Uncertain
Boomers Need the Safest Dividend Stocks. We Asked Claude and Found 5 That Yield 5% or More
1 Dividend King to Buy Hand Over Fist Right Now
Best Consumer Dividend Stocks to Buy Now: HAS, KVUE, MOV
Diamond Hill Select Fund Q1 2026 Portfolio Update
Best Income Stocks to Buy for May 26th
KVUE or LRLCY: Which Is the Better Value Stock Right Now?
Kimberly-Clark positioned for long-term value creation following Kenvue deal, says Bank of America
New Strong Buy Stocks for May 11th